Anecdotal evidence that cannabis preparations have medical benefits together with the
discovery of the psychotropic plant cannabinoid Δ9-tetrahydrocannabinol (THC) initiated …

Background Comprehensive literature reviews of historical perspectives and evidence
supporting cannabis/cannabinoids in the treatment of pain, including migraine and …

The golden age of cannabis pharmacology began in the 1960s as Raphael Mechoulam and
his colleagues in Israel isolated and synthesized cannabidiol, tetrahydrocannabinol, and …

To present a summary of current scientific evidence about the cannabinoid, cannabidiol
(CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders …

Cannabidiol (CBD) is a non-intoxicating and generally well-tolerated constituent of cannabis
which exhibits potential beneficial properties in a wide range of diseases, including …

Cannabidiol (CBD) is a phytocannabinoid with therapeutic properties for numerous
disorders exerted through molecular mechanisms that are yet to be completely identified …

Intrapartum-related events are the third leading cause of childhood mortality worldwide and
result in one million neurodisabled survivors each year. Infants exposed to a perinatal insult …

The mechanism of action of cannabidiol (CBD), the main non-psychotropic component of
Cannabis sativa L., is not completely understood. First assumed that the compound was …

Heavy cannabis use has been frequently associated with increased rates of mental illness
and cognitive impairment, particularly amongst adolescent users. However, the …

Cannabidiol (CBD) has been traditionally used in Cannabis-based preparation, however
historically, it has received far less interest as a single drug than the other components of …